Business Description
Bone Biologics Corp
NAICS : 325412
SIC : 3842
ISIN : US0980702049
Description
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.91 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 19.5 | |||||
3-Year EPS without NRI Growth Rate | 38.1 | |||||
3-Year FCF Growth Rate | -0.7 | |||||
Future 3-5Y EPS without NRI Growth Rate | 45.56 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 54.1 | |||||
9-Day RSI | 49.22 | |||||
14-Day RSI | 49.36 | |||||
6-1 Month Momentum % | -65.28 | |||||
12-1 Month Momentum % | -76.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 11.2 | |||||
Quick Ratio | 11.2 | |||||
Cash Ratio | 8.18 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -118.6 | |||||
Shareholder Yield % | -56.41 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -134.91 | |||||
ROA % | -109.54 | |||||
ROIC % | -1313.63 | |||||
ROC (Joel Greenblatt) % | -1427.95 | |||||
ROCE % | -130.56 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.67 | |||||
Price-to-Tangible-Book | 0.72 | |||||
EV-to-EBIT | -0.07 | |||||
EV-to-EBITDA | -0.07 | |||||
EV-to-FCF | -0.05 | |||||
Price-to-Net-Current-Asset-Value | 0.72 | |||||
Price-to-Net-Cash | 1.02 | |||||
Earnings Yield (Greenblatt) % | -1428.57 | |||||
FCF Yield % | -254.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BBLG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bone Biologics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -9.761 | ||
Beta | -0.27 | ||
Volatility % | 120.17 | ||
14-Day RSI | 49.36 | ||
14-Day ATR ($) | 0.32917 | ||
20-Day SMA ($) | 1.7825 | ||
12-1 Month Momentum % | -76.33 | ||
52-Week Range ($) | 1 - 10.56 | ||
Shares Outstanding (Mil) | 1.8 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Bone Biologics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Bone Biologics Corp Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Bone Biologics Corp Frequently Asked Questions
What is Bone Biologics Corp(BBLG)'s stock price today?
The current price of BBLG is $1.59. The 52 week high of BBLG is $10.56 and 52 week low is $1.00.
When is next earnings date of Bone Biologics Corp(BBLG)?
The next earnings date of Bone Biologics Corp(BBLG) is 2024-11-14 Est..
Does Bone Biologics Corp(BBLG) pay dividends? If so, how much?
Bone Biologics Corp(BBLG) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |